kallikrein

Biologicalexperimental

Kallikreins are a subgroup of serine proteases, enzymes capable of cleaving peptide bonds in proteins. In humans, plasma kallikrein has no known paralogue, while tissue kallikrein-related peptidases (KLKs) encode a family of fifteen closely related serine proteases. These genes are localised to chromosome 19q13, forming the largest contiguous cluster of proteases within the human genome. Kallikreins are responsible for the coordination of various physiological functions including blood pressure, semen liquefaction and skin desquamation. — Wikipedia

Clinical trial activity

5 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
3

Earliest trial started Aug 1, 2015 (NCT02562183)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • kallikrein
  • kallikrein

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06380699Phase 1Mar 16, 2023Government of China, Nanjing University
NCT06388772Phase 1Jul 5, 2021Government of China, Nanjing University
NCT04102956Phase 4Jul 1, 2017Hebei University
NCT04325932Phase 4Jan 31, 2016Zhejiang University
NCT02562183Phase 4Aug 1, 2015Techpool Bio-Pharma Co., Ltd., Tsinghua University
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of ChinaGovernment2212021
Nanjing UniversityAcademic/Hospital2012021
Hebei UniversityAcademic/Hospital1112017
Techpool Bio-Pharma Co., Ltd.For profit1112015
Tsinghua UniversityAcademic/Hospital1012015
Zhejiang UniversityAcademic/Hospital1112016
6 organizations
Page 1 / 1